T Cure Bioscience https://validator.w3.org/feed/docs/rss2.html News Management PIPELINE PARTNERS Technology Home Careers Thank You for Contacting Us October 5, 2021 – <strong><span style="text-transform: uppercase;">T-CURE BIOSCIENCE, INC. AND ATLAS ANTIBODIES AB ENTER A COLLABORATION AGREEMENT FOR THE DEVELOPMENT, MANUFACTURE, AND SUPPLY OF CT83 (KK-LC-1) MONOCLONAL ANTIBODIES</span></strong> Contact September 15, 2021 – <strong><span style="text-transform: uppercase;">T-CURE BIOSCIENCE ANNOUNCES U.S. FDA CLEARANCE OF INVESTIGATOR – INITIATED CLINICAL TRIAL FOR KK-LC-1 TCR-T AGAINST MULTIPLE SOLID TUMORS</span></strong> iSORT Platform June 14, 2023 – T-CURE BIOSCIENCE ANNOUNCES DR. GANG ZENG GUEST SPEAKER AT TWO UPCOMING IMMUNOTHERAPY SUMMITS September 10, 2021 – <strong><span style="text-transform: uppercase;">T-CURE BIOSCIENCE ANNOUNCED PRESENTATIONS AT THREE UPCOMING HEALTHCARE CONFERENCES</span></strong> August 04, 2020 – <strong><span style="text-transform: uppercase;">T-Cure Bioscience Announces Expansion of Collaboration With the National Institutes of Health for T Cell Receptor (TCR) Therapy Targeting HERV-E for the Treatment of Kidney Cancer</span></strong> TCR THERAPY April 08, 2020 – <strong>T-CURE BIOSCIENCE SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH NCI</strong> Current Openings About January 20, 2021 – <strong><span style="text-transform: uppercase;">T-Cure Bioscience and Immunotech Biopharm Ltd. Announce License Agreement for Novel HERV-E T Cell Receptor Therapy</span></strong> April 16, 2021 – <strong><span style="text-transform: uppercase;">T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that management will present virtually at the following upcoming webinar and healthcare conference:</span></strong> April 20, 2020 – <strong>T-CURE ANNOUNCES APPOINTMENT OF SEASONED INDUSTRY EXECUTIVE JAMES G. MCARTHUR, PH.D. TO BOARD OF DIRECTORS</strong> Privacy Terms of Use March 17, 2021 – <strong><span style="text-transform: uppercase;">T-Cure Bioscience Enters Into Agreement With Rutgers to Conduct Clinical Research of Novel T Cell Receptor Therapy for Treatment of Variety of Cancers</span></strong> SCIENTIFIC AND MEDICAL ADVISORY BOARD October 6, 2022 – <strong><span style="text-transform: uppercase;">NCI AND RUTGERS UNIVERSITY OPEN PHASE 1 CLINICAL TRIALS OF T CELL RECEPTOR THERAPY TARGETING KK-LC-1 FOR MULTIPLE SOLID TUMORS</span></strong>